Prescriptions for controversial drug shot up 250% for cancer patients after Mel Gibson endorsement

Prescriptions for ivermectin-fenbendazole among cancer patients reportedly jumped more than 2.5x after Mel Gibson’s January 2025 appearance on Joe Rogan’s podcast, with the South seeing more than 3x 2024 levels. The article says there is no high-quality human evidence that the drugs are safe or effective for cancer, and experts warn patients may be delaying proven therapies. The findings are from a UCLA-led study and do not prove the podcast caused the spike, but they highlight risks from unproven medical advice spreading through media.

Analysis

The marketable takeaway is not the drugs themselves but the speed and shape of demand creation when celebrity health claims bypass medical gatekeepers. That matters most for any business exposed to attention-driven consumer behavior: one high-reach media event can create a short-lived but very real prescription shock, especially in cohorts already predisposed to distrust mainstream care. The second-order risk is that these surges are likely to be geographically and demographically concentrated, which makes them easier to exploit for telehealth, compounding, and cash-pay channels while also increasing scrutiny on prescribers and dispensers.

The more investable implication is regulatory spillover. If this pattern persists, expect a faster response from state medical boards, pharmacy benefit managers, and platform moderators rather than FDA alone, because the behavior change is happening upstream of traditional approval pathways. That creates a near-term tailwind for companies tied to compliance, claims adjudication, and prior-auth controls, while raising reputational and legal risk for any telemedicine or direct-to-consumer pharmacy platform that becomes associated with off-label ivermectin/fenbendazole traffic.

The contrarian view is that the trade may be larger in sentiment than in economic impact. Even a 2.5x prescription jump is coming off a tiny base, so the revenue delta for most public companies is probably immaterial unless a distributor or cash-pay clinic cluster has meaningful concentration. The bigger alpha is in anticipating which intermediaries get blamed if adverse events emerge or if patients delay standard oncology care; that is where litigation and reimbursement risk can expand over months, not days.

For biotech/pharma, this also highlights the persistent market for low-evidence repurposing narratives. If a real oncology catalyst later disproves any signal, the backlash could compress demand abruptly, but until then the more probable path is intermittent attention spikes rather than durable adoption. Investors should think in terms of option-like exposure to regulatory headlines and social amplification, not fundamental healthcare penetration.

Key Decisions for Investors

• Short any public telehealth or cash-pay pharmacy name with evidence of ivermectin-heavy traffic on the next 1-3 month horizon; use a tight stop if management guidance explicitly excludes the segment and the stock de-risks quickly.
• Buy call spreads on health IT / utilization management names such as TDOC-adjacent or PBM-linked exposure if available via ETFs (e.g., IYH) over 3-6 months; the thesis is that prior auth, claims edits, and compliance workflows see modest but durable volume uplift from this episode.
• Avoid going long any pure-play alternative-medicine or DTC supplement platform into the next 30-60 days; upside is mostly attention-driven, while downside from regulatory scrutiny or reputational contagion is asymmetric.
• If you can source an optionsable pharma-services or distributor name with oncology-adjacent exposure, consider a small long-volatility structure into earnings; the catalyst is not revenue but headline risk around reimbursement, adverse events, or prescriber discipline.
• Pair trade: long managed-care / utilization control names vs. short speculative telehealth over 2-4 months, targeting a modest mean-reversion spread if regulators and payers tighten standards around off-label prescribing.